Biologics:how far can they go in Crohn’s disease?

作     者：Katie A.Dunleavy Darrell S.Pardi 

作者机构：Division of Gastroenterology and HepatologyMayo ClinicRochesterMNUSA 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2022年第10卷第1期

页      面：155-170页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Crohn’s disease medical treatment biologics anti-TNFs anti-integrins anti-interleukins JAK inhibitors S1Pinhibitors 

摘      要：Crohn’s disease is a chronic gastrointestinal inflammatory disorder,characterized by episodes of relapsing and remitting *** the disease mechanism becomes better elucidated,there is a significant increase in the number of available biologic *** article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn’s disease and examines the positioning of medical therapy as emerging biologics break onto the market.